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Background: Goodpasture’s disease (GP) is mediated by autoantibodies that
bind the glomerular and alveolar basement membrane, causing rapidly progressive
glomerulonephritis with or without pulmonary hemorrhage. The autoantibodies bind
neoepitopes formed upon disruption of the quaternary structure of α345NC1 hexamer,
a critical structural domain of α345 collagen IV scaffolds. Hexamer disruption leads to
a conformational changes that transitions α3 and α5NC1 subunits into immunogens,
however, the trigger remains unknown. This contrasts with another anti-GBM disease,
Alports’ post-transplant nephritis (APTN), where the pathogenic alloantibody binds
directly to native NC1 hexamer. The current report includes the first study of antigenic
specificity and allo-incompatability in anti-GBM disease occurring after allogeneic
haematopoietic stem cell transplant (HSCT).
Results: The anti-GBM antibodies were found to be directed predominantly against the
EA epitope of the α3 NC1monomer of collagen IV and developed rapidly in patient serum
reaching peak level within 5 weeks. Autoantibody binding to native α345NC1 hexamer
was minimal; however, binding was greatly increased upon dissociation of the native
hexamer. There were no polymorphic genetic differences between donor and recipient
collagen IV genes which would be predicted to cause a significant NC1 conformational
change or to provide a target for antibody binding. Both patient and donor possessed
the Goodpasture’s susceptibility HLA-allele DRB1∗1501.
Conclusions: The current report includes the first in-depth study of allo-incompatability
and antigenic specificity in anti-GBM disease occurring after allogeneic haematopoietic
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stem cell transplant (HSCT). No polymorphic genetic differences were identified between
donor and recipient collagen IV genes which would be predicted to provide a target for
antibody binding. Furthermore, autoantibody binding to native α345NC1 hexamer was
minimal, increasing greatly upon dissociation of the native hexamer, resembling wild-type
GP diseases and marking this as the first example of a post-HSCT conformeropathy.
Keywords: Goodpastures, glomerular basement membrane, conformeropathy, GvHD, anti-GBM, alloimmunity,
autoimmunity
INTRODUCTION
Goodpasture’s (GP) disease is mediated by autoantibodies,
commonly known as anti-GBM antibodies, that target α345
scaffold of collagen IV of the kidney glomerular (GBM) and
lung alveolar basement membrane causing rapidly progressive
glomerulonephritis and pulmonary hemorrhage. In GP disease,
the autoantibodies bind neoepitopes formed on α3 and α5
NC1 subunits upon disruption of the quaternary structure of
native α345NC1 hexamer, a critical structural domain of α345
collagen IV scaffolds (1, 2). Hexamer disruption is concomitant
with conformational changes that transitions subunits into
immunogens. The pathogenesis of the ensuing anti-GBM
nephritis contrasts with that of Alport’s post-transplant nephritis
(APTN). In APTN, α345 collagen IV scaffold is seen as foreign
within the transplanted kidney, owing to its absence in the
GBM of the recipient Alport patient. Of particular importance,
while both auto- and alloantibodies target the same α345NC1
hexamer, they bind different epitopes (1). In GP disease, epitopes
are formed after dissociation of hexamer subunits, whereas
in APTN alloantibody epitopes are located on the surface of
the α345NC1 hexamer (3, 4). The trigger for conformational
changes that transition subunits into immunogens in GP disease
remains unknown. We describe the first case of anti-GBM
disease occurring post haematopoietic stem cell transplant where
the pathogenesis including antibody specificity and the local
determinants of antibody binding have been extensively studied.
We previously reported the first patient with X-linked
lymphoproliferative (XLP) disease-associated cerebral vasculitis
to successfully undergo a hematopoietic stem cell transplant
(HSCT) (5). However, at day +169 post-transplant the
patient developed anti-GBM disease, a complication rarely
reported post-HSCT. This case presented a unique opportunity
to investigate whether the anti-GBM nephritis phenocopied
alloimmune response, as in APTN, or autoimmune response, as
in GP disease. In addition, serum from this patient was available
prior to and during the onset of anti-GBM disease, providing a
window into both the emergence, evolution, antibody specificity,
and the temporal relationship between antibody production and
the development of renal failure.
MATERIALS AND METHODS
Patient serum was collected prior to the onset of anti-
GBM disease and through the time when plasma exchange
and immunosuppressive drug treatment were initiated. Serum
collected at the disease onset at dilutions of 1:50 to 1:250 was
applied to frozen sections of normal human kidney, and binding
of circulating anti-GBM antibody to the normal GBM was
detected using fluorescein labeled anti-IgG secondary antibody.
For immunoadsorbtion, patient serum was preincubated with
NHS-activated magnetic beads coated with 100 µg/mg of
recombinant α3NC1 domain of collagen IV. In a separate
experiment, immunofluorescent staining was also performed
after treatment of normal kidney sections with 6M urea in 0.1M
glycine-HCl, pH 2.2 for 10min prior to addition of GP serum.
Antigens and Anti-GBM ELISA
Recombinant human α1NC1 through α6NC1 domains of
collagen IV in monomer form and α3/α1 chimeras were purified
from culture medium of stably transfected human embryonic
kidney (HEK) 293 cells using anti-FLAG agarose as previously
described (6). α3/α1NC1 chimeras corresponding to the EA
and EB epitopes of the α3NC1 domain were constructed
by PCR mutagenesis as previously described (7). The native
NC1 hexamers of collagen IV were isolated from bovine or
human GBM after collagenase digestion and size-exclusion
FPLC chromatography. Binding of antibody to recombinant
NC1 domains or chimeras was performed using indirect
enzyme-linked immunosorbent assay, with alkaline phosphatase-
conjugated goat anti-human IgG or IgM (Sigma, 1:2,000)
secondary antibody as described (1).
Sequencing and Analysis
Next generation gene sequencing was performed by the Bristol
genetics laboratory using theHaloPlex Target Enrichment System
kit including all coding regions for a range of basement
membrane associated genes. Analysis was focused specifically
on the COL4A3, COL4A4, and COL4A5 genes to identify
non-reference sequence variations (hg19) between donor and
recipient, which were assessed using the Grantham score of
physicochemical change.
Statistical Analysis
The results for all quantitative experiments are reported as
mean ± SD of three independent experiments. To determine
differences between groups, we used analysis of variance with
multiple groups comparison by Holm-Sidak method (SigmaStat)
with P < 0.05 considered to indicate statistical significance.
RESULTS
A 12-year-old boy underwent unrelated cord blood transplant
(UCBT) for X-linked lymphoproliferative (XLP) disease caused
by a mutation c.96G>C in the SH2D1A gene. The patient’s
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primary disease has been reported elsewhere regarding novel
features of XLP, with presentation including cerebral vasculitis,
aplastic anemia, acute respiratory distress syndrome, and
arthropathy (5). Features of the transplant potentially pertinent
to the current investigations include that an initial 6/6 HLA
matched UCBT failed to engraft and he underwent a second
transplant with a 5/6 matched UCBT, which engrafted with
100% donor chimerism. His main side effects during the acute
phase of the transplant were BK virus-associated hemorrhagic
cystitis with bladder perforation and a possible NK cell
immune reconstitution syndrome, including bilateral pulmonary
infiltrates. At 169 days post-transplant when he had been
engrafted and well for some time, he presented with fever,
hematuria and acute renal failure, and was identified as having
anti-GBM antibodies on indirect immunofluorescence of serum
and characteristic crescentic glomerulonephritis injury with
direct linear GBM immunofluorescence staining for IgG on
renal biopsy. He was treated with plasmapheresis for 1 month
with initial 2nd daily exchanges, high dose corticosteroids and
cyclophosphamide before having B-cell depletion with rituximab.
He went into remission, becoming anti-GBM antibody negative,
with residual moderate chronic kidney disease. He is currently
well with a glomerular filtration rate of 43 ml/min/1.73 m2, with
no proteinuria or hematuria.
The biopsy showed characteristic features of crescentic
glomerulonephritis, with >90% of the 32 glomeruli sampled (8
globally sclerosed) displaying cellular or fibrocellular crescents,
with segmental fibrinoid necrosis and with extensive acute
tubular injury and focal, 10–20% interstitial fibrosis and tubular
atrophy (Figure 1A). When applied to frozen sections of normal
human kidney, the patient’s serum at 1:50 dilution demonstrated
strong linear anti-GBM staining, which was greatly enhanced
by acidic urea treatment (Figures 1B,C). The specificity of the
staining and the nature of deposited antibody were established
by immunoadsorbtion of serum on α3NC1-coated magnetic
beads, which nearly abolished staining in parallel with removal
of α3NC1 antibody (Figures 1E,F). The findings are diagnostic
of severe anti-GBM antibody-mediated glomerulonephritis.
Serum collected at initial presentation showed that a majority
of antibody targeting the α3NC1 monomer of collagen IV
with weaker reactivity against α1 and α5NC1 monomers,
indicating that α3NC1 is the primary autoantigen (Figure 2A).
This was further supported by measuring the affinity of
circulating antibodies toward human α1, α3, and α5NC1
domains (Figure 2B). Patient serum was pre-incubated with
increasing concentrations of the NC1 monomers and binding
to immobilized α1, α3, and α5NC1, respectively was measured
by inhibition ELISA. The strongest inhibition by the α3NC1
monomers indicates that the anti-α3 antibodies have highest
affinity, followed by the anti-α5, and low affinity anti-α1
antibody. Furthermore, adsorption of patient serum on α3NC1-
coated magnetic beads not only removes α3 specific antibodies,
but significantly reduces immunoreactivity to α1 and α5NC1
(Figure 2C), indicating at least partial cross-reactivity of the
major α3-specific antibody with the α1 and α5NC1 domains.
Circulating antibodies from the HSCT patient targeted
predominantly the EA epitope of α3NC1 monomer with lower
reactivity toward EB epitope (Figure 2D) suggesting a key role of
the EA region in the initiation of anti-GBM disease in this case.
This is consistent with previously reported EA-specific antibody
titers as a primary predictor of renal outcome in Goodpasture’s
disease (8) and proven pathogenicity of EA-α3 chimeric protein
in rat model of glomerulonephritis (9). Since targeting of
the additional non-GP epitopes could not be excluded in
this type of assay, we performed the competition ELISA for
antibody binding to the α3NC1 domain. For this experiment,
GP antibodies were purified by affinity chromatography on
α3NC1 domain coupled to agarose beads and labeled with biotin.
Patient serum antibodies efficiently competed with binding
of biotinylated GP antibody to coated α3NC1 in a dose-
dependent manner and was undistinguishable from the control
mix of GP sera (Figure 2E), showing that current patient’s
circulating antibody targets the same epitopes as in patients with
classical GP disease.
Finally, although there was minimal antibody reactivity
with native α345NC1 hexamers from bovine or human GBM,
binding of antibody was significantly increased upon hexamer
dissociation by a protein denaturant (Figure 2F). This closely
resembled the enhanced immunofluorescent staining of human
kidney sections after acidic urea (Figure 1C). Therefore, in
terms of epitope specificity and binding to dissociated NC1
hexamers, the anti-GBM antibodies in the current post-HSCT
case clearly phenocopy classical Goodpasture autoantibodies, but
not APTN alloantibodies.
ELISA analysis revealed the rapid development of antibodies
to the α3NC1 monomer of collagen IV in patient serum over
a period of 5 weeks (Figure 2G). Surprisingly, we did not
detect IgM reactivity to any of collagen IV NC1 domains either
prior or or at the onset of the anti-GBM disease (Figure 2H).
By quantitative analysis using purified GP antibodies as
standard, we found that concentration of α3-specific IgG
reached peak concentration about 400µg/ml or 4% of total
IgG, which is considerably higher than ∼1% median value for
GP patients.
Given that there is a strong association between susceptibility
to Goodpasture’s disease and HLA DRB1∗15:01 (10–12), we also
assessed theHLA alleles and found that both the recipient and the
donor of the cord blood, which engrafted 100%, carried a single
Goodpasture’s associated HLA DRB1∗15:01 allele.
We then questioned whether the pathogenesis of anti-GBM
disease in this HSCT patient involved alloreactivity between
the incoming donor immune system and genetic variation in
the recipient’s α345 collagen IV scaffold. An absence of genetic
alterations within the part of theCOL4A3 gene encoding the NC1
domain in Goodpasture’s patients has been reported previously,
suggesting that NC1 mutations are not a major factor in the
etiology of classical Goodpasture’s disease (13). However, we
hypothesized that genetic variations may occur in HSCT patient
that alters the fine specificity of T and B cell tolerance to α3NC1
or the structure of the of the recipient’s α345 NC1 hexamer. Such
an alteration could promote appearance of the abnormally folded
NC1 hexamer or an unassembled full length α3 chain recognized
as foreign to the incoming donor immune system and thereby
inducing antibody production.
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FIGURE 1 | (A) Kidney lesions in post-HSCT patient showing characteristic features of crescentic glomerulonephritis, with >90% of the 32 glomeruli sampled
displaying cellular or fibrocellular crescents, with segmental fibrinoid necrosis and with extensive acute tubular injury and focal, 10–20% interstitial fibrosis and tubular
atrophy (Jones’ silver stain). (B–E) Binding of patient serum antibodies to frozen sections from normal human kidney (immunofluorescent staining). (B) Distinct linear
staining of GBM observed on intact kidney section, which is strongly increased after pre-treatment with acidic urea (C). (D) There is no staining with normal human
serum (1:50). (E) GBM staining was abolished by adsorption of patient serum on α3NC1-coated magnetic beads (E), which removed 95% of α3-antibody as
demonstrated by testing of original (GP) and absorbed (MB) serum using indirect ELISA of on α3NC1-coated plate (F).
We detected two missense variants in each of COL4A3
and COL4A4, and none in COL4A5 genes in the recipient,
but not in the donor, which are listed in Table 1. Mutation
mapping shows that all four variants fall within the triple-helical
region of COL4A4/COL4A3 chains distant to the target EA-α3
and EB-α3 epitopes of the NC1 domain (Figure 3) and would
not be predicted to directly influence the quaternary structure
of the native α345NC1 hexamer. No variants were detected
which differed between donor and recipient, in the α3, α4 or
α5NC1 domains.
DISCUSSION
Autoimmune disease occurring post-HSCT, i.e., antibodies
from the graft against “self,” is not uncommon, and is more
common with transplants are performed for certain monogenic
indications (14). Wiskott Aldrich syndrome, a disease which
predisposes to autoimmunity, is associated with a high rate of
post-transplant autoimmunity, a predilection which is associated
with reduced donor cell chimerism (15). HSCT for another
entity, chronic granulomatous disease, may also predispose
to a high risk of autoimmune cytopenias, neuropathy and
thyroid disease (16), and in this case the tendency appears
to occur despite excellent donor cell engraftment. There is no
particular predilection reported of post-transplant autoimmunity
in patients transplanted for XLP1.
The post-HSCT antibody-mediated disease where there is the
greatest knowledge of antigenic target is autoimmune haemolytic
anemia. Preformed recipient allo-antibodies against donor
derived red cells resemble red cell alloantibodies important
for transfusion reactions, and are therefore well-understood
(17). However, there is little information of antigenic targets
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FIGURE 2 | (A) Testing of NC1 domain specificity at the onset of the disease by ELISA showed that antibodies targeted predominantly α3NC1 domain with a lesser
reactivity to α1 and α5NC1 domains. (B) Patient serum was pre-incubated with increasing concentrations of the α1, α3, and α5NC1 monomers and binding to
corresponding immobilized monomers was measured by ELISA. Differential sensitivity to inhibition by the three NC1 monomers indicates that α3 antibodies has the
highest affinity. (C) Pre-adsorption of patient serum with α3NC1-coated magnetic beads (MBser) significantly reduced immunoreactivity to α1 and α5NC1 monomers
compared to original serum (GPser). (D) α3NC1-specific antibodies predominantly target the EA epitope with lower reactivity to EB epitope. (E) Binding of purified GP
antibody labeled with biotin to α3NC1 monomer was competed by patient serum (Pt), as well as control serum mix from 8 GP patients (GP), but not by the normal
human serum (N). (F) Patient’s antibodies strongly react with the denatured NC1 hexamers from bovine (bGBM) or human (hGBM) glomerular basement membrane,
while minimally react with native NC1 hexamers. (G) ELISA analysis of serial serum samples demonstrated the absence of anti-GBM antibodies 5 weeks prior to
presentation (12/30/2013) by comaprison with normal human serum (NHS), with a rapid and strong development of immunoreactivity in 5 weeks. (H) There was no
IgM binding to any of the six human recombinant NC1 domains of collagen IV in serum samples collected before or at the onset of the disease. The dashed line
indicates threshold determined as mean ± 3x SEM for normal human serum.
and in particular epitope specificities involved in less common
post-HSCT allo- or autoimmune entities, with the exception of
data on the cell surface targets of antibodies relevant to chronic
graft vs. host disease (GVHD) (18).
The current patient is the first described case of anti-GBM
disease post-cord blood transplant. Two cases of anti-GBM
nephritis were reported originating as a graft-vs.-host (GVH)
phenomenon post hematopoietic stem cell transplant (HSCT).
Frontiers in Immunology | www.frontiersin.org 5 November 2019 | Volume 10 | Article 2659
Gray et al. Goodpastures Disease Post-HSCT
TABLE 1 | Missense variants in genes encoding collagen IV chains.
Variant Gene gnomAD MAF SNP ref. Amino acid change Grantham score
g.2,228163453,C,A COL4A3 4.7% rs57611801 Asp1269Glu 45
g.2,228121101,G,T COL4A3 16.7% rs55703767 Asp326Tyr 160
g.2,227946893,C,G COL4A4 2.8% rs1800516 Gly545Ala 60
g.2,227915832,G,A COL4A4 52% rs1800517 Pro1004Leu 98
The gnomAD (r2.0.2) allele frequency (AF) reflects that these are common variants, however the Grantham scores (range 5–215) reveal that in particular rs55703767 (radical change),
might be expected to impose a significant effect on the physicochemical properties of the α3 chain of collagen IV. MAF, minor allele frequency.
FIGURE 3 | Patient-restricted coding variants within type IV collagen proteins. Domain architecture and relative locations of missense variants within COL4A3
(Uniprot: Q01955) and COL4A4 (Uniprot: P53420) proteins that differed between the patient and the cord-blood donor. No patient-restricted variants were observed
in COL4A5. The black bars represent anti-GBM disease-associated EA-α3 and EB-α3 epitopes.
A 42-year-old female patient received a bone marrow transplant
(BMT) and developed systemic vasculitis with a combination of
anti-neutrophil cytoplasmic (ANCA) and anti-GBM antibodies
(19). In another study, a series of biopsies in patients suffering
renal disease post-HSCT identified a single case of an elderly
BMT patient with anti-GBM disease (20). Neither of these
cases was analyzed with regard to antigen specificity of anti-
GBM antibody.
Given the rarity of anti-GBM nephritis post-HSCT, we
determined whether the specificity and binding properties of the
anti-GBM antibodies of the HSCT patient resembled those of
APTN or GP disease. This disease involved a donor immune
system and genetically mismatched kidney, similar to the case
with APTN, and therefore we had anticipated that the antibodies
would behave analogous to that of APTN alloantibodies by
binding to the native α345NC1 hexamer, and specifically to
the α3 or α5NC1 subunits. Surprisingly, the HSCT antibodies
did not bind the native α345NC1 hexamer but bound to
the dissociated α3 and α5NC1 subunits via the EA and EB
neoepitopes. Thus, the anti-GBM antibodies of the HSCT
patient phenocopied GP autoantibodies. Furthermore, no genetic
variants were found in the recipient collagen IV genes which
might have led to a structural perturbation in the immunogen,
eliciting antibody production.
We conclude that this is a case of classical Goodpasture’s
disease, as shown by the specificity of the antibodies
phenocopying that of antibodies bound to native kidney
and elicited by the native immune system of GP patients.
These antibodies emerged post transplantation from a donor
immune system. But what caused this patient to suffer this
novel complication? The properties of his circulating antibodies,
which were non-reactive to the native α345NC1 hexamer, but
fully reactive to dissociated α3NC1 subunit, strongly suggest
that the inciting immunogen was the dissociated subunit
harboring the EA and EB neoepitopes. This supposition is
supported by the finding that native α345NC1 hexamer is
not pathogenic in an animal model of GP disease, whereas
immunization with hexamer dissociated by acid treatment
induced glomerulonephritis (21, 22). Yet, in the unique case
of APTN, the native hexamer elicited alloantibody production,
revealing it to be the immunogen in the kidney allograft (3, 4).
While it is not possible to pinpoint the inciting factor that
triggered hexamer dissociation into immunogenic subunits
in the HSCT case, several possibilities exist. For example,
after transplant he suffered an episode of bilateral pulmonary
infiltrates, which could cause structural damage to the α345NC1
hexamer in the alveolar basement membrane (23), transitioning
subunits into immunogens. Such a structural damage in lungs
could also occur due to a bacterial or one of his viral infections
(BK, HHV-7) or by the immunosuppression therapy. Indeed,
lung injury has been associated with GP disease etiology, wherein
cigarette smoking and inhalation of hydrocarbons are risk factors
in numerous patients (24, 25).
The process of immune reconstitution may be relevant for
GP disease etiology in HCT patients. The current paradigm
suggests that the loss of tolerance in autoimmune disease is
often a failure of multiple checkpoints that ultimately unmask
autoreactive T and B cells (26). There have been reports of anti-
GBM disease occurring with recovery following alemtuzemab
treatment (27). Further, patients with HIV/AIDS, who have
severe immune dysregulation, develop frequent autoantibodies,
including anti-GBM, although anti-GBM disease is very rare
(28). Both recipient and donor were homozygous for the HLA
allele associated with Goodpasture’s disease, HLA DRB1∗15:01
(DR15) (11, 12). Homozygosity at the DR locus meant that
there was no expression of dominantly protective DR allomorphs
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such as DR1 or DR7 (10), setting the scene for the loss of
tolerance to α3NC1 under unfavorable conditions. In the context
of DR15, central tolerance to α3NC1 is poor, as CD4+ Foxp3−
conventional T cells even from healthy people bearing DR15
react with the immunodominant T cell epitope α3135−145, and
can be differentiated into effector Th1 cells, Th17 cells and T
follicular helper (Tfh) cells (12). Antigen-specific Tfh cells are
critical in generating antibody responses to most antigens, likely
including the Goodpasture antigen. As the Tfh subset is deficient
in SH2D1A deficiency (29), in our patient aberrant or exuberant
reconstitution resulting in the development of autoreactive Tfh
cells may have played a role in loss of tolerance to α3NC1 and the
generation of anti-GBM antibodies.
The availability of serum prior to and during early stages
of anti-GBM disease in this HSCT patient provided a unique
opportunity to assess the time frame for development of GP
disease. The case demonstrated the rapidity, in a matter of
weeks, with which a patient can go from being antibody
negative to accumulating high titers of pathogenic antibody
with development of rapidly progressive glomerulonephritis.
Importantly, our findings reiterate the ultimate importance for
early diagnosis and timely treatment (30) with potential recovery
of kidney function despite very high level of circulating α3
and α5NC1 antibodies. Furthermore, our patient shows that the
antibody phenocopies the autoimmune GP disease, rather than
the antibody specificity seen in Alport patients with anti-GBM
developing after kidney transplant.
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